Overview

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
To test the safety of and effectiveness of XmAb20717 for participants with advanced rare cancers.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center